Navigation Links
Evaluate Report to Examine Life After the Patent Cliff, Provides Analysis on Pharmaceutical and Biotech Markets and Consensus Forecasts to 2018
Date:6/13/2013

LONDON and BOSTON, June 13, 2013 /PRNewswire/ --

Patent expirations in 2012 have put the industry through an unprecedented decline in worldwide prescription drug sales in 2012. Now that the pharmaceutical industry has faced the biggest patent cliff it has ever seen, Evaluate Ltd. will examine its effects and what the industry can expect through 2018 in its upcoming annual World Preview report. Evaluate will release the report, which is based on EvaluatePharma® data, on Monday, June 24 in conjunction with the DIA 2013 49th Annual Meeting in Boston, MA.

The EvaluatePharma World Preview 2013 Edition will include:

  • Worldwide prescription and generic drug sales through 2018
  • Sales at risk due to patent expirations through 2018
  • Sales by therapy area through 2018
  • Global pharmaceutical R&D spend
  • FDA new drug approval analysis
  • Top grossing companies and products by market
  • M&A and venture funding analysis

For more information on the 2013 Edition of the World Preview report and to receive your complimentary copy of the Executive Summary, please visit the Evaluate booth #630 at DIA. The summary and full report will be available on the Evaluate web site beginning June 24, 2013. Follow @evaluatepharma on Twitter for a reminder.

If you are attending the 2013 DIA Annual Meeting or the EphMRA 2013 conference and would like to meet, please Contact Us.

About Evaluate Ltd.

Established in 1996, Evaluate Ltd. is the leader in high quality life science sector analysis. EvaluatePharma delivers exclusive consensus forecasts and trusted commercial insight into biotech and pharmaceutical performance. EvaluateMedTech sets a new standard in integrated analysis and consensus forecasts of the global medical device and diagnostic industry. EvaluateClinical Trials delivers unique intelligence to efficiently and accurately analyze the global clinical trial landscape. A team of over 85 dedicated healthcare analysts employ rigorous methodologies to collate, organize and deliver the most-up-to-date commercial performance data available. An award winning editorial team of journalists writing under the EP Vantage name support EvaluatePharma's analysis. The Evaluate services enable the life science community to make sound business decisions about value and opportunity. For more information please visit http://www.evaluategroup.com. On Twitter: @evaluatepharma, @evaluatemedtech, @epclinicaltrial, @epvantage.

Media Contacts:
Evaluate and EP Vantage
Christine Lindgren
+1-617-866-3906
christine.lindgren@evaluategroup.com

Chempetitive Group (for US media)
Rachel Lear
Kelly Quigley
+1-781-775-3640
rlear@chempetitive.com

College Hill (for non-US media)
Melanie Toyne Sewell / Stephanie Bacher / Gemma Howe
+44(0)20-7457-2020
evaluate@collegehill.com


'/>"/>
SOURCE Evaluate Ltd.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Marketing Services Groups Face Constant Pressure to Evaluate and Evolve their Organization
2. Inovalon Partners with Pharmacy Quality Alliance to Evaluate Medication Adherence Quality Performance Measure
3. Soligenix Receives IND Clearance from FDA to Initiate Clinical Program to Evaluate SGX942 for the Treatment of Oral Mucositis
4. Trovagene and Barretos Cancer Hospital, Brazil, to Evaluate Urine-Based HPV Assay as Potential Pap Smear Replacement
5. Avaxia Biologics Receives IND Clearance from FDA to Initiate Clinical Program to Evaluate AVX-470 as Therapy for Ulcerative Colitis
6. Study Published In Contraception Evaluates Medical Expenditures For Unintended Pregnancies And Potential Cost Impact Of Increased Use Of Long-Acting Reversible Contraception
7. EvaluatePharma Appoints Alexander Karle as COO
8. Terumo Completes U.S. Patient Enrollment in the OSPREY Trial to Evaluate the MISAGO Self-expanding Stent
9. Researchers Evaluate Computer-based Treatment for People with Schizophrenia
10. EvaluatePharma Names Debbie Paul CEO, Americas to Lead Growth in Key Region
11. U.S. News & World Report Honors 7 SynCardia Certified Centers Among "Best Childrens Hospitals" for Cardiology and Heart Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... Ariz. , May 3, 2016  As a ... twice contracted rheumatic fever, which damaged his heart. He ... But by June 2013, Shepherd,s heart was giving ... from death. On June 20, 2013, the ... Total Artificial Heart (TAH-t). Like a heart transplant, the ...
(Date:5/3/2016)... OSWEGO, Ore. , May 3, 2016 /PRNewswire/ ... endovascular medical technology, today announced Food and Drug ... cardiac resynchronization defibrillator that provides heart failure patients ... scans. Iperia devices also have remote monitoring with ... that adapts the heart rate in response to ...
(Date:5/3/2016)... May 3, 2016   BIOTRONIK will be ... care beyond the implant at the Heart Rhythm Society,s ... San Francisco . ... highest quality of patient care and satisfaction possible. Part ... each and every tomorrow," said Marlou Janssen , ...
Breaking Medicine Technology:
(Date:5/4/2016)... Carlsbad, CA (PRWEB) , ... May 04, 2016 , ... ... has recently partnered with local company MitoXcell in preparation of the launch of her ... day jump start plan is a nutritional guide designed to jump start a new ...
(Date:5/4/2016)... ... May 04, 2016 , ... The preeminent surgical aftercare ... Dickinson needed following breast cancer surgery. In March 2016, the 61-year-old model and reality ... breast cancer that occurs in the milk ducts, according to an interview with ...
(Date:5/4/2016)... ... ... Advanced Spine & Sport Medical Rehabilitation Center, which is renowned for its ... seminar on stem cell injections. The seminar is scheduled for Wednesday, May 18, from ... Suite 110, Ventura, CA. There are only 10 seats available. , “The purpose ...
(Date:5/4/2016)... ... May 04, 2016 , ... ... and support for knees, ankles, and elbows. Engineered with athletes in mind, ... flat-bed manufacturing (opposed to ineffective circular knitting, common in the industry) produces ...
(Date:5/4/2016)... , ... May 03, ... manufacturer of innovative infant and child products, today revealed the non-toxic ... ability to help babies deal with teething pain is just part ... no toxic gels, and are BPA-, PVC-, and phthalate-free. , ...
Breaking Medicine News(10 mins):